首页> 外文期刊>BMC Public Health >Protective efficacy of malaria case management and intermittent preventive treatment for preventing malaria mortality in children: a systematic review for the Lives Saved Tool
【24h】

Protective efficacy of malaria case management and intermittent preventive treatment for preventing malaria mortality in children: a systematic review for the Lives Saved Tool

机译:疟疾病例管理和间歇性预防性治疗对预防儿童疟疾死亡率的保护功效:拯救生命工具的系统评价

获取原文
           

摘要

Background The Lives Saved Tool (LiST) model was developed to estimate the impact of the scale-up of child survival interventions on child mortality. New advances in antimalarials have improved their efficacy of treating uncomplicated and severe malaria. Artemisinin-based combination therapies (ACTs) for uncomplicated Plasmodium falciparum malaria and parenteral or rectal artemisinin or quinine for severe malaria syndromes have been shown to be very effective for the treatment of malaria in children. These interventions are now being considered for inclusion in the LiST model. However, for obvious ethical reasons, their protective efficacy (PE) compared to placebo is unknown and their impact on reducing malaria-attributable mortality has not been quantified. Methods We performed systematic literature reviews of published studies in P. falciparum endemic settings to determine the protective efficacy (PE) of ACT treatment against malaria deaths among children with uncomplicated malaria, as well as the PE of effective case management including parenteral quinine against malaria deaths among all hospitalized children. As no randomized placebo-controlled trials of malaria treatment have been conducted, we used multiple data sources to ascertain estimates of PE, including a previously performed Delphi estimate for treatment of uncomplicated malaria. Results Based on multiple data sources, we estimate the PE of ACT treatment of uncomplicated P. falciparum malaria on reducing malaria mortality in children 1–23 months to be 99% (range: 94-100%), and in children 24-59 months to be 97% (range: 86-99%). We estimate the PE of treatment of severe P. falciparum malaria with effective case management including intravenous quinine on reducing malaria mortality in children 1-59 months to be 82% (range: 63-94%) compared to no treatment. Conclusions This systematic review quantifies the PE of ACT used for treating uncomplicated malaria and effective case management including parenteral quinine for treating severe P. falciparum malaria for preventing malaria mortality in children <5. These data will be used in the Lives Saved Tool (LiST) model for estimating the impact of scaling-up these interventions against malaria. However, in order to estimate the reduction in child mortality due to scale-up of these interventions, it is imperative to develop standardized indicators to measure population coverage of these interventions.
机译:背景技术救生工具(LiST)模型的开发是为了估计扩大儿童生存干预措施对儿童死亡率的影响。抗疟药的新进展提高了它们治疗简单和严重疟疾的功效。事实证明,以青蒿素为基础的联合疗法(ACTs)可用于治疗单纯性恶性疟原虫疟疾和肠胃外或直肠青蒿素或奎宁用于严重疟疾综合征,对儿童疟疾的治疗非常有效。现在正在考虑将这些干预措施纳入LiST模型。但是,出于明显的伦理原因,与安慰剂相比,它们的保护功效(PE)尚不清楚,并且它们对降低疟疾可归因的死亡率的影响尚未量化。方法我们对恶性疟原虫流行环境的已发表研究进行了系统的文献综述,以确定ACT治疗对单纯性疟疾患儿疟疾死亡的保护效果(PE),以及包括肠外奎宁对疟疾死亡的有效病例管理的PE在所有住院儿童中。由于尚未进行关于疟疾治疗的随机安慰剂对照试验,因此我们使用多个数据源来确定PE的估计值,包括先前进行的Delphi估计值,用于单纯性疟疾的治疗。结果基于多个数据源,我们估计ACT治疗非复杂性恶性疟原虫对降低1-23个月儿童疟疾死亡率的PE为99%(范围:94-100%)和24-59个月儿童为97%(范围:86-99%)。我们估计,通过有效的病例管理(包括静脉注射奎宁)可降低1至59个月儿童疟疾死亡率,并通过有效的病例管理,与未治疗相比,恶性疟原虫疟疾的PE为82%(范围:63-94%)。结论本系统评价量化了用于治疗单纯性疟疾和有效病例管理的ACT的PE,包括肠胃外奎宁治疗严重恶性疟原虫疟疾以预防5岁以下儿童疟疾死亡率的方法。这些数据将用于“保存生命的工具(LiST)”模型中,以评估扩大这些干预措施对疟疾的影响。但是,为了估计由于这些干预措施的扩大而导致的儿童死亡率的降低,必须制定标准化指标来衡量这些干预措施的人口覆盖率。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号